Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)

Summary

Asthma can be caused by a variety of factors, including tobacco smoke, allergens, and respiratory airway infections. Many people use inhaled corticosteroid medications to treat their symptoms. These medications, however, are not effective for everyone. Clarithromycin is an antibiotic that may effectively treat asthma in these individuals. This study will evaluate the effectiveness of clarithromycin at controlling asthma symptoms.

Conditions

• Asthma

Interventions

DRUG

clarithromycin

clarithromycin 500 mg twice daily (Biaxin)

DRUG

fluticasone propionate

fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)

DRUG

placebo clarithromycin

placebo clarithromycin twice daily

Sponsors & Collaborators

• National Heart, Lung, and Blood Institute (NHLBI)

  collaborator NIH

• Milton S. Hershey Medical Center

  lead OTHER

Principal Investigators

• William J. Calhoun, MD · University of Texas, Galveston

• Mario Castro, MD · Washington University School of Medicine

• Robert F. Lemanske, MD · University of Wisconsin, Madison

• Richard J. Martin, MD · National Jewish Health

• Elliot Israel, MD · Brigham and Women's Hospital

• Stephen P. Peters, MD, PhD · Wake Forest University Health Sciences

• Homer A. Boushey, MD · University of California, San Francsico

• Stephen I. Wasserman, MD · University of California, San Diego

• Emily DiMango, MD · Columbia University

• Monica Kraft, MD · Duke University

• Reuben M Cherniack, MD · National Jewish Health

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2006-06-30

Primary Completion

2009-04-30

Completion

2009-04-30

Countries

• United States

Study Locations